Gauging physician awareness of nucleic acid-based therapies.
Despite the buzz, physicians have limited familiarity and understanding with the burgeoning category of nucleic acid-based therapies, writes Meghan Oates-Zalesky.
Expedited reviews drive new imperative for iteration and quality data that enable agility and results.
Data shows cultural gaps and highlights a C-level fix.